(no text — see the shared post below)
FDA approved low-dose colchicine for CV risk reduction, including multiple risk factors
Louis notes that the FDA approved low-dose colchicine to reduce cardiovascular events, working by lowering arterial inflammation. Per the Medscape report, it is the first specific anti-inflammatory drug for this purpose in people with established atherosclerotic disease or multiple risk factors.
